Comparing Penumbra (PEN) and Apollo Endosurgery (APEN)
Penumbra (NYSE: PEN) and Apollo Endosurgery (NASDAQ:APEN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.
This is a breakdown of current ratings for Penumbra and Apollo Endosurgery, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Penumbra presently has a consensus price target of $98.00, suggesting a potential upside of 6.99%. Apollo Endosurgery has a consensus price target of $11.00, suggesting a potential upside of 105.99%. Given Apollo Endosurgery’s higher possible upside, analysts clearly believe Apollo Endosurgery is more favorable than Penumbra.
Institutional and Insider Ownership
70.9% of Penumbra shares are held by institutional investors. Comparatively, 8.9% of Apollo Endosurgery shares are held by institutional investors. 13.5% of Penumbra shares are held by company insiders. Comparatively, 74.2% of Apollo Endosurgery shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Penumbra and Apollo Endosurgery’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Penumbra has a beta of 0.09, suggesting that its stock price is 91% less volatile than the S&P 500. Comparatively, Apollo Endosurgery has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500.
Valuation and Earnings
This table compares Penumbra and Apollo Endosurgery’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Penumbra||$294.09 million||10.52||-$3.32 million||($0.27)||-339.25|
|Apollo Endosurgery||$63.01 million||1.46||-$10.53 million||N/A||N/A|
Penumbra has higher revenue and earnings than Apollo Endosurgery.
Penumbra beats Apollo Endosurgery on 7 of the 11 factors compared between the two stocks.
Penumbra Company Profile
Penumbra, Inc. is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. It focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Neuro Thrombectomy (Ischemic Stroke), Neurovascular Embolization (Brain Aneurysms) and Neurosurgical Tools (Hemorrhagic Stroke). Its peripheral vascular products include Peripheral Vascular Embolization and Peripheral Thrombectomy.
Apollo Endosurgery Company Profile
Apollo Endosurgery, Inc., formerly Lpath, Inc., is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries. The Company’s products include ORBERA, LAP-BAND and OverStitch. The Company’s product, ORBERA, is a gastric balloon. The ORBERA Intragastric Balloon System is a weight loss aid for adults suffering from obesity. The LAP-BAND System is a minimally invasive procedure that offers weight loss. The LAP-BAND System is indicated for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope. OverStitch offers solutions for defects in both the upper and lower gastrointestinal tract.
Receive News & Ratings for Penumbra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.